Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(HE)3-ZHER3-ABD-mcDM1
- Development stage
- Preclinical
- Lead developer
- Uppsala University
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Administration
- Intravenous
01
Overview
(HE)3-ZHER3-ABD-mcDM1 is a preclinical-stage, HER3-targeted affibody-drug conjugate (AffiDC) developed by researchers at Uppsala University and KTH Royal Institute of Technology. The construct consists of a HER3-targeting affibody molecule (ZHER3) fused to an albumin-binding domain (ABD) for in vivo half-life extension, and an N-terminal (HE)3 tag (His-Glu-His-Glu-His-Glu) for site-specific radiolabeling (e.g., with technetium-99m). It is conjugated to the cytotoxic microtubule inhibitor payload DM1 (mertansine) via a non-cleavable maleimidocaproyl (mc) linker. In preclinical models of HER3-expressing cancers, such as pancreatic cancer and prostate cancer, the conjugate has demonstrated high binding specificity, efficient internalization, and potent cytotoxicity.
- Other names
- [99mTc]Tc-(HE)3-ZHER3-ABD-mcDM1[99mTc]Tc-ZHER3-ABD-mcDM1ZHER3-ABD-mcDM1ZHER-3-ABD-mcDM1ZHER 3-ABD-mcDM1
02
Targets
ERBB3 (Erb-b2 receptor tyrosine kinase 3)
Beyond the preview
Go deeper on (HE)3-ZHER3-ABD-mcDM1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on (HE)3-ZHER3-ABD-mcDM1.